Hal Barron Leaves GSK With A Stronger Pipeline But Still Awaiting Inflection
R&D Spending Still Lags Behind Peers
Executive Summary
Research chief Barron is departing before his turnaround of GSK is fully realized but the consumer division spin-out could unlock new R&D money to help it challenge the sector’s leaders.